Advertisement
Home »

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).

May 15, 2023

ABOUT THE CONTRIBUTORS

  • Keith S Kaye

    Division of Allergy, Immunology and Infectious Diseases, Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: kk1116@rwjms.rutgers.edu.

    Andrew F Shorr

    Pulmonary and Critical Care Medicine, MedStar Washington Hospital, Washington, DC, USA.

    Richard G Wunderink

    Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

    Bin Du

    State Key Laboratory of Complex, Severe and Rare Diseases, Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

    Gabrielle E Poirier

    Entasis Therapeutics, Waltham, MA, USA; Nimbus Therapeutics, Cambridge, MA, USA.

    Khurram Rana

    Entasis Therapeutics, Waltham, MA, USA.

    Alita Miller

    Entasis Therapeutics, Waltham, MA, USA.

    Drew Lewis

    Entasis Therapeutics, Waltham, MA, USA.

    John O’Donnell

    Entasis Therapeutics, Waltham, MA, USA.

    Lan Chen

    Global Development, Neuroscience, Autoimmune and Infectious Diseases, Zai Lab, Shanghai, China.

    Harald Reinhart

    Global Development, Neuroscience, Autoimmune and Infectious Diseases, Zai Lab, Shanghai, China.

    Subasree Srinivasan

    Entasis Therapeutics, Waltham, MA, USA; The Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.

    Robin Isaacs

    Entasis Therapeutics, Waltham, MA, USA.

    David Altarac

    Entasis Therapeutics, Waltham, MA, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


RECOMMENDED ARTICLES FOR YOU

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RECOMMENDED ARTICLES FOR YOU

Advertisement